“…5,6 During the COVID-19 pandemic, in addition to the pulmonary and neurological manifestations, the alteration of the coagulation pathway soon appeared significant, which represented the rationale for the use of heparin. 5,7,8,9,10,11,12,13,14,15,16 This alteration resulted both in the form of hypercoagulability 11,14,17 with expressions of a thromboembolic nature (e.g. PTE, DVT), whose mechanism is still necessary to investigate, 13 and in the form of haemorrhagic diathesis with depletion of coagulation factors, thrombocytopenia and hyperfibrinolysis.…”